Published on 24/12/2025
How to Evaluate Vendor Regulatory Compliance History in Clinical Trials
Introduction: Why Compliance History Matters
When qualifying vendors for clinical trials, sponsors must go beyond reviewing technical capabilities and financial stability. One of the most critical aspects is assessing the vendor’s regulatory compliance history. A vendor’s past performance during inspections, audits, and regulatory reviews provides important insight into potential risks. Regulators such as the FDA, EMA, and MHRA expect sponsors to document how vendor compliance history was evaluated and used in qualification decisions. Failure to adequately assess this area can lead to findings, trial delays, or rejection of trial data.
1. Regulatory Framework Supporting Compliance History Evaluations
Vendor compliance history reviews are supported by multiple international requirements:
- ICH-GCP E6(R2): Sponsors must oversee all trial-related duties performed by vendors.
- FDA BIMO Program: Focuses on sponsor oversight, including vendor compliance with GCP.
- EMA EU CTR 536/2014: Requires sponsors to ensure vendors are qualified and compliant, with records available in the Trial Master File (TMF).
- MHRA GCP Inspections: Frequently cite inadequate vendor compliance evaluations as findings.
These frameworks make compliance history evaluation a mandatory component of vendor due diligence.
2. Sources of Vendor Compliance History
Sponsors can obtain compliance history from multiple sources:
- FDA inspection databases
3. Key Elements to Review in Compliance History
When assessing vendor compliance, sponsors should review:
- Inspection Frequency: How often the vendor has been inspected.
- Inspection Outcomes: Whether findings were minor, major, or critical.
- CAPA Effectiveness: Evidence that issues were addressed in a timely manner.
- Recurrence of Findings: Repeated issues indicate weak quality systems.
- Transparency: Willingness of the vendor to share inspection and audit records.
4. Example Compliance History Review Matrix
| Vendor | Regulatory Findings | CAPA Implemented | Risk Level |
|---|---|---|---|
| CRO A | FDA 483 – delayed SAE reporting | CAPA verified, training implemented | Medium |
| Central Lab B | EMA inspection – incomplete assay validation | CAPA pending, follow-up audit scheduled | High |
| IT Vendor C | No regulatory findings in last 5 years | N/A | Low |
5. Case Study: Compliance History Driving Qualification Decision
Scenario: A sponsor reviewing a CRO’s compliance history found multiple unresolved FDA 483s related to informed consent documentation. While the CRO had strong technical expertise, the unresolved CAPAs raised concerns.
Resolution: The sponsor conditionally qualified the CRO, limiting its scope of services until CAPAs were closed. A follow-up audit was performed to confirm improvements. This risk-based approach allowed trial progress while maintaining oversight.
6. Best Practices for Evaluating Compliance History
- Incorporate compliance history reviews into vendor qualification SOPs.
- Cross-check vendor-provided information against public regulatory databases.
- Apply risk-based scoring models to compliance findings.
- Reassess vendor compliance history annually or before major contracts.
- Document all compliance history evaluations in the TMF for inspection readiness.
Conclusion
Evaluating regulatory compliance history is essential to vendor due diligence in clinical trials. Sponsors must review inspection findings, CAPA effectiveness, and regulatory transparency to determine whether vendors are reliable partners. By embedding compliance history assessments into qualification SOPs and documenting outcomes, sponsors can demonstrate robust oversight, minimize risks, and ensure the integrity of outsourced clinical research.